Material and Methods

Study design
Nasopharyngeal wash (using Cheiron Dynamic II apparatus) and blood samples were prospectively obtained from patients less than 2 years of age with a bronchiolitis. Patient enrolment occurred 7 days a week and samples were taken within 24 hours after first contact with the hospital. Only patients with an RSV infection, as determined by PCR retrospectively, were included in the study. Exclusion criteria were: immunodeficiency, systemic steroid treatment in the previous 2 weeks, blood transfusion, congenital heart and chronic lung disease. Patients were followed until recovery and were retrospectively classified as: mild for children without hypoxia, moderate for patients requiring supplemental oxygen (oxygen saturations <90%, ≥10 minutes) and severe for children requiring mechanical ventilation due to apnea, exhaustion and/or respiratory failure. Recovery samples were obtained after 4-6 weeks, during home visits. Blood samples were obtained from healthy patients without underlying diseases or medication subjected to elective surgery.
Sample processing and blood transcriptome profiling
Multiplex RT-PCR was performed to test the nasopharyngeal washes on 15 different viral pathogens, as previously described (E1) . Blood was collected in Tempus tubes and stored at -80°C. Total RNA was isolated from the blood using Tempus Spin RNA isolation kit (Applied Biosystems, Bleiswijk, The Netherlands). Globin mRNA was removed from total RNA preparations using the Globinclear kit (Life Technologies). RNA concentrations and OD 260/280 ratios were measured with the NanoDrop ND-1000 UV-VIS spectrophotometer (NanoDrop Technologies, Wilmington, USA). Assessment of RNA quality and purity was performed with the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). RNA (200ng) was labelled using the MessageAmp Premier RNA Amplication kit (Applied Biosystems) and hybridized to Human Genome U133 plus 2 gene chips (Affymetrix), according to the manufacturer's recommendations. Image analysis was performed using GeneChip Operating Software (Affymetrix). Microarray Suite version 5.0 software (Affymetrix) was used to generate .dat and .cel files.
Differential expression analysis
For = 1 … samples and = 1, … , transcripts (probesets) the linear model for each probeset was as follows:
Where Y i is a vector of the expression values of probeset i, Status is an indication matrix of the samples by RSV categories and β i is a vector of coefficients of the RSV categories for probeset i. The DE analysis was then performed by comparing the contrasts of Status for each probeset.
Identification and evaluation of prognostic biomarkers
Given that we are interested in genomic prognostic biomarker(s), we retained a sex by age standardized dataset by fitting the linear models in equation (1) above using limma (E2) and from those models the sex by age standardized expression set was:
As class labels, we combined the mild and moderate groups as one class (class 0) with focus on predicting severe cases (class 1) from others. For clinical application, a prediction of the probability to progress to severe disease is of primary interest than direct classification (E3). Therefore, using results of (E4, E5) and the observed correlation distribution shown on supplementary Fig. S2 three classification functions were chosen. These classification functions were support vector machines (SVM) with a linear kernel (E6,) , shrunken centroids discriminant analysis (SCDA) also known as prediction analysis of microarray (PAM) (E7) and random forest (RF) (E8).
For each classification function, a prediction model was built and evaluated using leave one out cross validation with an inner loop of 5-fold cross validation for parameter(s) optimization as shown on Fig. S6 step 1, optimizing the parameters by maximizing the binomial log-likelihood function. We evaluated the prediction models using calibration score (CS) and refinement score (RS) (E5) which is a decomposition of the Brier score. The calibration score expresses on one hand, how well the predicted probabilities agree with the true chances of patients and it is equal to zero in case of perfect agreement. On the other hand, the refinement score expresses how uncertain the predicted probabilities are; that is how close the predicted probabilities are to 0.5. The closer the predicted probabilities are to 0.5, the higher the uncertainty and the poorer the model. A good class prediction model has a CS and RS of zero. The best calibrated and refined function amongst the three classification functions ( For the chosen classification function, the model was built on the entire dataset with a 5-fold cross validation for parameter(s) optimization based on maximizing the binomial log-likelihood function.
The list of transcripts from the optimal parameter(s) was retained (Fig. S6, step 3) as a gene signature.
Logistic regression models
Let be the leave one out cross-validated predicted probability of sample to progress to severe state by a genomic signature, then the genomic score is given as:
). The general logistic regression model is then written as:
where ( ) is the probability of sample to progress to severe state, a vector or matrix of predictive parameters (i.e. Genomic score, Age, and/or Sex) and is a vector of parameter (s) estimate(s). Let be the predicted value of sample from equation (3), the probability of that sample to progress to severe state is computed from its predicted value using the inverse logistic function as:
With these predicted probabilities, the AUCs were computed.
Validation of biomarkers
For an independent (external) validation, a subset of the Illumina RSV data set of (E9) was used. Since the experimental data and validation data are from different platforms, we opted to link the data using gene symbols. To achieve this, the signature transcripts were annotated to gene symbols and unannotated transcripts were eliminated if any (Fig. S6, step 4) . The Illumina data was also annotated to gene symbols ( 
The scaled Illumina data was then predicted using our prognostic model (step 12) and the validating ability of the model was evaluated (steps 13 and 14) of the same For a confirmatory analysis of our validation performance, using the chosen classification function we built class prediction model on the entire Illumina data using LOOCV as shown on step 1 of Fig. S6 .
We then compared our validation performance to the performance that can be achieved on this data with the chosen function. 
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